Rubinstein–Taybi syndrome

Rubinstein–Taybi syndrome
Other namesBroad thumb-hallux syndrome or Rubinstein syndrome[1]
Child displaying characteristic facial features of Rubinstein–Taybi syndrome
SpecialtyMedical genetics Edit this on Wikidata
Causesmutation or deletion in the CREBBP gene, located on chromosome 16, and/or the EP300 gene, located on chromosome 22.

Rubinstein–Taybi syndrome (RTS) is a rare genetic condition characterized by short stature, moderate to severe learning difficulties, distinctive facial features, and broad thumbs and first toes.[2] Other features of the disorder vary among affected individuals. These characteristics are caused by a mutation or deletion in the CREBBP gene, located on chromosome 16, and/or the EP300 gene, located on chromosome 22.[3]

This condition is sometimes inherited as an autosomal dominant pattern, but often as a de novo. It affects an estimated 1 in 125,000-300,000 births.

Signs and symptoms

Rubinstein-Taybi Syndrome is characterized by intellectual disability, distinct facies, and atypical growth.[4]

Facial features (A), left hand and feet showing broad thumb and big toes (B, C) and X-ray of both hands showing sho

Anatomical & musculoskeletal

Typical facial characteristics include a small chin and small oral cavity.[4]

Other characteristics, which may vary by genetic cause of the disorder, include the following:

  • Broad thumbs[5][4]
  • Broad first toes[5]
  • Clinodactyly of the 5th finger[5]
  • Radially-deviated thumbs[4]
  • Broad toes, which may cause difficulty walking and may be so severe in a minority of patients as to require surgical intervention.[4]

Hypermobility is common, which may lead to stiffness and a waddling gait.

Developmental

During pregnancy, pre-eclampsia is highly common. Rates of pre-term and full-term birth match those found among the general population. While birth parameters are generally normal, there is a higher incidence of microcephaly and growth restriction than among the general population, possibly due to the higher preeclampsia rates.[4]

Although size at birth is normal, children with the disorder will generally not grow as fast as their peers, and will generally fall to about 2 standard deviations below their peer's heights, weights, and head circumferences. Children affected by the disorder will not experience a growth spurt during puberty, leading to adult heights, weights, and head circumferences around 3 standard deviations below normal. Growth hormone (GH) deficiency is rare but possible, and can cause the child to go further below the growth patterns of typically developing children.[4]

Gastroenterological

Neonatal breastfeeding difficulties are present in roughly three quarters of affected individuals because of swalling miscoordination, poor nipple grasp, hypotonia, and gastroesophogeal reflux disease (GORD). This leads to roughly 40% of babies requiring feeding support, up to and including PEG tubes. Very rarely, eosiniphilic estrophagitis may form.[4]

There may be a higher rate of gastroentological complications among individuals with the disorder; namely, duodenal web and GI tract malrotation.[6][7][4] Constipation is highly common.[8][4][6]

Cardiopulmonary

Congenital heart defects occur in about 30% of cases, among which the most common are patent ductus arteriosus, persistent foramen ovale, atrial septal defect, and ventricular septal defect.

Hypertension occurs in 10% of adults,[9][4] and is caused by renal artery stenosis.[4]

Mild respiratory distress is common in newborns, and upper respiratory infections are common over the lifespan. Lower respiratory infections are less common and, when present, often caused by the aforementioned gastroenterological problems.[4]

Interstitial lung disease is rare, but can occur.[4] Pulmonary functioning can be lowered due to scoliosis, and chronic sleep apnoea can cause pulmonary hypertension.

Endocrinological

A small number of newborns and young children with the condition will experience transient hypoglycemia, which can be well-managed. Hyperinsulinemic hypoglycemia is very rare, but can occur, especially if the disorder is caused by an EP300 variant.[4]

Opthalmalogical

Ocular abnormalities and reduced vision are present at a higher rate in this population. There is a higher incidence of watery eye due to congenital issues in this population. Glaucoma is rare; it can be unilateral or bilateral and can be associated with anterior segment anomalies such as iris coloboma or ectopia lentis that can cause tearing, blepharospasm, photophobia, and enlargement of the eye manifesting as megalocornea and rapidly increasing myopia. The coloboma is reported in 10% of individuals and can affect any or all of following structures: iris, choroid, retina, or optic nerve.[4]

Up to a quarter of individuals with RTS will have cataracts, generally in the first two months of life but sometimes later on which are often congenital.[4]

Retinal abnormalities are frequent in this population.[a][4]

Visual impairment occurs in a fifth of patients,[10][4] often caused by the anatomical abnormalities associated with the condition. In severe cases, infantile nystagmus may follow from decresed sensory input from the eyes starting at birth. Refractive errors and strabismus occur in half to three quarters of individuals, and their severity may change rapidly.[4]

Otolaryngological

Recurrent middle ear infections can be caused by airway difficulties, which are themselves caused by the GORD and unique facial structures.[11][4] This may cause conductive, sensorineural, and mixed hearing loss.[4]

Hypnological

Sleep can be affected by the facial abnormalities and increased laryngeal wall collapsibility. Sleep disorders are frequent, occurring moreso in children than adults. The risk of sleep disorders in children can be increased by more abnormal facial features, hypotonia, and adenotonsilar hypertrophy.[12][4]

Intellectual

A 2009 study found that children with RTS were more likely to be overweight and to have a short attention span, motor stereotypies, and poor coordination. The study hypothesized that the identified CREBBP gene impaired motor skills learning.[13] Other research has shown a link with long-term memory (LTM) deficit.[14][15]

Dermatological

Keloids are the primary skin issue experienced by patients with the condition, the risk for which can be amplified or reduced by patient-specific and environmental factors.[4] Keloids cannot develop spontaneously except in genetic conditions, and RTS provides the highest risk of keloid development.[16][4] However, cancer risk isn't elevated due to these keloids.[4][17]

Pilomatricomas are also a risk of the disease. Puberty is often a triggering factor.[4]

Ingrown nails, congenital generalized hypertrichosis that becomes less marked with age, melanocytic naevi, white papulae on the limbs and trunk, additional nipples, lentigines, and café-au-lait spots are other findings associated with the condition.[4]

Urinogenitary

23% of individuals with RTS have urinary tract anomalies, including horseshoe kidney, renal duplication, renal agenesis, renal dysplasia, hydronephrosis, nephrolithiasis and vesicoureteral reflux.[4] Renal artery stenosis can cause hypertension in children with the condition.[4]

Shawl scrotum formation is common. 59% of men have cryptorchidism on one or both sides. Hypospadias in both sexes and labia minora fusion are rarer.[4] Uterine malfunctions are rare.[4][18] Female patients may have hypermenorrhagia or metrorhaggia.[4]

Genetics

Rubinstein–Taybi syndrome is inherited in an autosomal dominant fashion.

Rubinstein–Taybi syndrome, in many cases, is a microdeletion syndrome involving chromosomal segment 16p13.3 and is characterized by mutations in the CREBBP gene.[19][20] Varying amounts of material are deleted from this section of the chromosome and account for the spectrum of physiological symptoms.[21]

The CREBBP gene makes a protein that helps control the activity of many other genes. The protein, called CREB-binding protein, plays an important role in regulating cell growth and division and is essential for normal fetal development. If one copy of the CREBBP gene is deleted or mutated, cells make only half of the normal amount of CREB binding protein. A reduction in the amount of this protein disrupts normal development before and after birth, leading to the signs and symptoms of Rubinstein–Taybi syndrome.[22][21]

Mutations in the EP300 gene, located on chromosome 22q13.2, are responsible for a small percentage of cases of Rubinstein–Taybi syndrome.[3] These mutations result in the loss of one copy of the gene in each cell, which reduces the amount of p300 protein by half. Some mutations lead to the production of a very short, nonfunctional version of the p300 protein, while others prevent one copy of the gene from making any protein at all. Although researchers do not know how a reduction in the amount of p300 protein leads to the specific features of Rubinstein–Taybi syndrome, it is clear that the loss of one copy of the EP300 gene disrupts normal development.

CREBBP and p300 are the respective protein products of the paralogous genes CREBBP and EP300. Both of these related proteins, prototypical members of the p300-CBP coactivator family, have a bromodomain and a histone acetyltransferase domain and are able to bind to various gene-specific transcription factors as well as general transcription factors.[23] Cell lines derived from RTS patients exhibit diminished acetylation of multiple histone proteins, particularly histone 2A and histone 2B,[24] suggesting that this disease has its origins in problems with the regulatory mechanisms of transcription.[25] The functions of CREBBP and p300 broadly overlap but do have co-activator–specific effects on gene expression.[26] The proteins may also facilitate transcriptional elongation.[27]

In approximately one third of the cases showing RTS symptoms, neither the CREBBP gene, nor the EP300 gene appear to be the cause of the disease.[3]

A mouse model has been identified in order to perform experimental research procedures. The mice exhibited the same clinical RTS symptoms seen in humans, and the model has become a foundation for future research.[28]

Diagnosis

RTS can be diagnosed through clinical features and can be confirmed through genetic testing.[29][4] However, 30% of cases do not have a known genetic basis.[29]

RTS is diagnosed when a heterozygous pathogenic variant of the CREBBP gene is identified in the individual. It exhibits an autosomal dominant inheritance pattern, but some documented cases show heterozygous individuals exhibiting germline mosaicism. This condition affects men and women equally, and is often misdiagnosed with other diseases or developmental disabilities.[citation needed]

Treatment

There is no existing treatment that reverses or cures RTS. There are, however, ways to manage and reduce symptoms for patients. Due to there being a wide range of symptoms, RTS patients are referred to specialists that focus on each specific symptom.[30] According to a meta-analysis of the condition in which diagnostic criteria were formed, the diagnostic workup of an infant with RTS should include glaucoma and coloboma opthalmalogical exams, cardiac assessment, and renal ultrasound. After diagnosis, male patients should also have a careful examination for cryptorchidism.[4]

GH deficiency can be treated in the normal manner in these patients.[4]

The coloboma cannot be cured, but the associated glare can be mitigated with the wearing of sunglasses. Frequent eye checkups are needed so that the corrective prescription may be modified correctly, especially below the age of 5. To prevent ambylopia, high refractive errors need correction.[4]

Individuals suffering from cognitive developments usually are part of special education programs and speech therapy. Regular check-ups and monitoring are needed for cardiac, dental, auditory, and renal abnormalities. Genetic counseling is also recommended for affected individuals and their families.[30]

Keloid treatment is difficult in patients with RTS; recurrence is high.[4]

Contraceptives can aid in treatment of menstrual issues sometimes experienced by patients.[4]

The broad toes of the condition may, in rare cases, require surgical intervention. Surgical intervention for thumb deviation may be less impactful due to the thumbs generally functioning well before surgery and common recurrence of the deviation after surgery.[4]

Anaesthesia and other surgical considerations

48% of adults with the disorder require surgery at least once, with half of them requiring two or more surgeries. Children with the disorder receive anaesthetics at a proportion higher than typically developing children.[4]

Anaesthesia may be dangerous in these patients. In some cases, individuals with Rubinstein–Taybi syndrome may have complications, such as respiratory distress and irregular heartbeats when the muscle relaxant succinylcholine or the anaesthetic atropine are administered.[4]

Primary literature suggests the children may have a higher rate of cardiac physical and conduction abnormalities which may cause unexpected results with cardioactive medications. Changes in the face and airway structure may making it more difficult to secure the airway under anaesthesia; rarely, the placement of nasopharyngeal or oropharyngeal airway devices may be inhibited due to unique anatomical structures. However, complications appeared in a minority of cases, and routine methods of airway control in the operating room appears to be successful.[4]

Laryngomalacia and augmented airway reactivity can complicate perioperative ventilation and post-exubation care.[4]

Opioid use is not contraindicated for pain management in these patients, but the meta-analysis urges "judicious" use of the medications to prevent apnoeas and the exacerbation of obstructive symptoms; it instead recommends the use of non-steroidal anti-inflammatory medications. It also recommends that procedures be bundled to reduce the risk of anaesthetic complications.[4]

According to the meta-analysis, polysomonography should be considered before surgery.[4][31]

History

Rubinstein–Taybi syndrome was first unofficially mentioned in a French orthopedic medical journal in 1957 by 3 Greek doctors. The medical journal reported a case concerning a seven-year-old boy with radically deviated/arched thumbs, long nose, muscular hypotonia, and physical and mental underdevelopment. At this point in time the case study mentioned by the Greek physicians was considered to be an anomaly due to the fact that there had not been any other reported cases of children with these specific physical and mental characteristics.

Rubinstein and Taybi, the doctors accredited with discovering the syndrome, were unaware of this journal at the time of their discovery. However, it is acknowledged that the 1957 case reported in the French journal of orthopedic medicine is most likely the first reported case of RTS.

Dr. Jack Herbert Rubinstein, an American pediatrician. reported assessing a three-year-old girl and a seven-year-old boy with unusual facial and digital findings in 1958. Having sensed a similarity between these two cases, Rubinstein tried distributing photos and information concerning these two cases to other clinics in the U.S. from 1959 to 1960.

In 1961, Dr. Hooshang Taybi, an Iranian-American pediatric radiologist, reported having assessed a three-year-old boy that appeared to have the same syndrome as described by Rubinstein. By the summer of 1963, Dr. Taybi reported having evaluated seven children with such characteristics as broad thumbs and great toes, unusual facial features, and intellectual disabilities – these findings went on to appear in the American Journal of Diseases of Children documenting these characteristics as a syndrome.

In 1992, the first genetic abnormalities that act as markers for Rubinstein-Taybi syndrome were identified. These abnormalities are said to affect either chromosome 16 or chromosome 22. The specific chromosome impacted by a mutation determines the type of Rubinstein–Taybi syndrome that may occur. A mutation of the CREBBP gene on chromosome 16 gives rise to the first form of RTS (most common), while a mutation of the EP300 gene on chromosome 22 is characteristic of the second form of RTS.

See also

Notes

  1. ↑ There is more on this subject in the cited paper, but it references an as-then unpublished paper by Van Genderen for that material, so I chose not to include it. I did a simple search to look for it and little was found, but another editor might could look again.

References

  1. ↑ Online Mendelian Inheritance in Man (OMIM): Rubinstein–Taybi syndrome - 180849
  2. ↑ Petrij, F; Dauwerse, HG; Blough, RI; Giles, RH; van der Smagt, JJ; Wallerstein, R; Maaswinkel-Mooy, PD; van Karnebeek, CD; van Ommen, GJ; van Haeringen, A; Rubinstein, JH; Saal, HM; Hennekam, RC; Peters, DJ; Breuning, MH (March 2000). "Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations". Journal of Medical Genetics. 37 (3): 168–76. doi:10.1136/jmg.37.3.168. PMC 1734540. PMID 10699051.
  3. 1 2 3 López M, García-Oguiza A, Armstrong J, García-Cobaleda I, García-Miñaur S, Santos-Simarro F, Seidel V, Domínguez-Garrido E (2018). "Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum". BMC Medical Genetics. 19 (1) 36. doi:10.1186/s12881-018-0548-2. PMC 5839060. PMID 29506490. Article No. 36.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 Lacombe, Didier; Bloch-Zupan, Agnès; Bredrup, Cecilie; Cooper, Edward B; Houge, Sofia Douzgou; García-Miñaúr, Sixto; Kayserili, Hülya; Larizza, Lidia; Lopez Gonzalez, Vanesa; Menke, Leonie A; Milani, Donatella; Saettini, Francesco; Stevens, Cathy A; Tooke, Lloyd; Van der Zee, Jill A (2024). "Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement". Journal of Medical Genetics. 61 (6): 503–519. doi:10.1136/jmg-2023-109438. ISSN 0022-2593. PMC 11137475. PMID 38471765.
  5. 1 2 3 Hennekam RC (Sep 2006). "Rubinstein-Taybi syndrome". Eur J Hum Genet. 14 (9): 981–985. doi:10.1038/sj.ejhg.5201594. PMID 16868563.
  6. 1 2 Rubinstein, J. H. (2005-06-03). "Broad thumb-hallux (Rubinstein-Taybi) syndrome 1957-1988". American Journal of Medical Genetics. 37 (S6): 3–16. doi:10.1002/ajmg.1320370603. PMID 2118774.
  7. ↑ Stevens, Cathy A. (October 2025). "Intestinal malrotation in Rubinstein–Taybi syndrome". American Journal of Medical Genetics Part A. 167 (10): 2399–2401. doi:10.1002/ajmg.a.37167. ISSN 1552-4825. PMID 26097216.
  8. ↑ "Rubinstein-Taybi Syndrome, Williams syndrome: American Journal of Medical Genetics: Vol 37, No S6". Wiley Online Library. doi:10.1002/ajmg.v37:6+ (inactive 30 June 2026).{{cite journal}}: CS1 maint: DOI inactive as of June 2026 (link)
  9. ↑ Douzgou, Sofia; Dell’Oro, Janet; Fonseca, Cristina Rodriguez; Rei, Alessandra; Mullins, Jo; Jusiewicz, Isabelle; Huisman, Sylvia; Simpson, Brittany N.; Vyshka, Klea; Milani, Donatella; Bartsch, Oliver; Lacombe, Didier; García-Miñaúr, Sixto; Hennekam, Raoul C. M. (2022-04-06). "The natural history of adults with Rubinstein-Taybi syndrome: a families-reported experience". European Journal of Human Genetics. 30 (7): 841–847. doi:10.1038/s41431-022-01097-8. ISSN 1018-4813. PMC 9259744. PMID 35388185.
  10. ↑ van Genderen, M. M (2000-10-01). "Ocular features in Rubinstein-Taybi syndrome: investigation of 24 patients and review of the literature". British Journal of Ophthalmology. 84 (10): 1177–1184. doi:10.1136/bjo.84.10.1177. ISSN 0007-1161. PMC 1723270. PMID 11004107.
  11. ↑ Stocks, Rose Mary S.; Egerman, Robert; Thompson, Jerome W.; Peery, Michael (April 2002). "Airway Management of the Severely Retrognathic Child: Use of the Laryngeal Mask Airway". Ear, Nose & Throat Journal. 81 (4): 223–226. doi:10.1177/014556130208100410. ISSN 0145-5613. PMID 11987739.
  12. ↑ Zucconi, Marco; Ferini-Strambi, Luigi; Erminio, Cristina; Pestalozza, Giulio; Smirne, Salvatore (2009-01-20). "Obstructive Sleep Apnea in the Rubinstein-Taybi Syndrome". Respiration. 60 (2): 127–132. doi:10.1159/000196186. ISSN 0025-7931. PMID 8341855.
  13. ↑ Galéra C, Taupiac E, Fraisse S, et al. (2009). "Socio-behavioral sharacteristics of children with Rubinstein–Taybi syndrome". J Autism Dev Disord. 39 (9): 1252–1260. doi:10.1007/s10803-009-0733-4. PMID 19350377. S2CID 5456561.
  14. ↑ Bourtchouladze R, Lidge R, Catapano R, et al. (September 2003). "A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4". Proceedings of the National Academy of Sciences of the United States of America. 100 (18): 10518–22. Bibcode:2003PNAS..10010518B. doi:10.1073/pnas.1834280100. JSTOR 3147748. PMC 193593. PMID 12930888.
  15. ↑ Alarcón JM, Malleret G, Touzani K, et al. (June 2004). "Chromatin acetylation, memory, and LTP are impaired in CBP± mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration". Neuron. 42 (6): 947–59. doi:10.1016/j.neuron.2004.05.021. hdl:10261/288998. PMID 15207239. S2CID 15669747.
  16. ↑ Kar, A.L.; Houge, G.; Shaw, A.C.; Jong, D.; Belzen, M.J.; Peters, D.J.M.; Hennekam, R.C.M. (September 2014). "Keloids in Rubinstein–Taybi syndrome: a clinical study". British Journal of Dermatology. 171 (3): 615–621. doi:10.1111/bjd.13124. ISSN 0007-0963. PMID 25132000.
  17. ↑ Siraganian, Patricia A.; Rubinstein, Jack H.; Miller, Robert W. (January 1989). "Keloids and neoplasms in the Rubinstein-Taybi syndrome". Medical and Pediatric Oncology. 17 (5–6): 485–491. doi:10.1002/mpo.2950170526. ISSN 0098-1532. PMID 2586363.
  18. ↑ de Castro Coelho, Filipa; Câmara, Sara; Alves, Inês; Brazão, Kathleen (January 2018). Pavone, Piero (ed.). "Septate Uterus in a Girl with Rubinstein–Taybi Syndrome". Case Reports in Pediatrics. 2018 (1) 7878156. doi:10.1155/2018/7878156. ISSN 2090-6803. PMC 5911335. PMID 29850348.
  19. ↑ Wójcik, C; Volz, K; Ranola, M; Kitch, K; Karim, T; O'Neil, J; Smith, J; Torres-Martinez, W (February 2010). "Rubinstein-Taybi syndrome associated with Chiari type I malformation caused by a large 16p13.3 microdeletion: a contiguous gene syndrome?". American Journal of Medical Genetics Part A. 152A (2): 479–83. doi:10.1002/ajmg.a.33303. PMID 20101707. S2CID 205312346.
  20. ↑ Petrij F, Giles RH, Dauwerse HG, et al. (July 1995). "Rubinstein–Taybi syndrome caused by mutations in the transcriptional co-activator CBP". Nature. 376 (6538): 348–51. Bibcode:1995Natur.376..348P. doi:10.1038/376348a0. PMID 7630403. S2CID 4254507.
  21. 1 2 Reference, Genetics Home. "Rubinstein-Taybi syndrome". Genetics Home Reference. Retrieved 2020-05-06. Public Domain This article incorporates text from this source, which is in the public domain.
  22. ↑ Milani, Donatella; Manzoni, Francesca Maria Paola; Pezzani, Lidia; Ajmone, Paola; Gervasini, Cristina; Menni, Francesca; Esposito, Susanna (2015-01-20). "Rubinstein-Taybi syndrome: clinical features, genetic basis, diagnosis, and management". Italian Journal of Pediatrics. 41 (1): 4. doi:10.1186/s13052-015-0110-1. ISSN 1824-7288. PMC 4308897. PMID 25599811.
  23. ↑ Freedman SJ, Sun ZJ, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ (2002). "Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α". Proceedings of the National Academy of Sciences of the United States of America. 99 (8): 5367–5372. Bibcode:2002PNAS...99.5367F. doi:10.1073/pnas.082117899. PMC 122775. PMID 11959990.
  24. ↑ Lopez-Atalaya JP, Gervasini C, Mottadelli F, Spena S, Piccione M, Scarano G, Selicorni A, Barco A, Larizza L (2012). "Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein–Taybi syndrome". Journal of Medical Genetics. 49 (1): 66–74. doi:10.1136/jmedgenet-2011-100354. hdl:2434/164984. PMID 21984751.
  25. ↑ Izumi K (2016). "Disorders of Transcriptional Regulation: An Emerging Category of Multiple Malformation Syndromes". Molecular Syndromology. 7 (5): 262–273. doi:10.1159/000448747. PMC 5109993. PMID 27867341.
  26. ↑ Ngan V, Goodman RH (2001). "CREB-binding Protein and p300 in Transcriptional Regulation". Journal of Biological Chemistry. 276 (17): 13505–13508. doi:10.1074/jbc.R000025200. PMID 11279224.
  27. ↑ Kasper LH, Qu C, Obenauer JC, McGoldrick DJ, Brindle PK (2014). "Genome-wide and single-cell analyses reveal a context dependent relationship between CBP recruitment and gene expression". Nucleic Acids Research. 42 (18): 11363–11382. doi:10.1093/nar/gku827. PMC 4191404. PMID 25249627.
  28. ↑ Oike, Y.; Hata, A.; Mamiya, T.; Kaname, T.; Noda, Y.; Suzuki, M.; Yasue, H.; Nabeshima, T.; Araki, K.; Yamamura, K. (March 1999). "Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism". Human Molecular Genetics. 8 (3): 387–396. doi:10.1093/hmg/8.3.387. ISSN 0964-6906. PMID 9949198.
  29. 1 2 Char R, Miller R, Riddle I, Sabido A, Schloemer C, Schorry E, Stevens C*, Wiley S. Understanding Rubinstein-Taybi Syndrome: A Guide for Families and Professionals. Cincinnati, OH, University of Cincinnati Center for Excellence in Developmental Disabilities (UCCEDD), Division of Developmental and Behavioral Pediatrics, Cincinnati Children’s Hospital Medical Center (CCHMC). 2019.
    • Department of Pediatrics, University of Tennessee College of Medicine, Chattanooga, Tennessee
  30. 1 2 "Rubinstein Taybi Syndrome". NORD (National Organization for Rare Disorders). Retrieved 2020-05-06.
  31. ↑ Roland, Peter S.; Rosenfeld, Richard M.; Brooks, Lee J.; Friedman, Norman R.; Jones, Jacqueline; Kim, Tae W.; Kuhar, Siobhan; Mitchell, Ron B.; Seidman, Michael D.; Sheldon, Stephen H.; Jones, Stephanie; Robertson, Peter (2011-06-15). "Clinical Practice Guideline: Polysomnography for Sleep-Disordered Breathing Prior to Tonsillectomy in Children". Otolaryngology–Head and Neck Surgery. 145 (S1): S1-15. doi:10.1177/0194599811409837. ISSN 0194-5998. PMID 21676944.
Wikimedia Commons logo
Wikimedia Commons has media related to Rubinstein-Taybi syndrome.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.